Upregulation of DLX4 increases the metastatic potential of breast cancer cells in vitro and in vivo [49, 54] and of prostate adenocarcinoma [51], and its expression correlates with advanced disease stage in ovarian cancer [50]. Here, DLX4 is linked to ovarian carcinoma.